The clinical efficacy and side-effect profile of atypical neuroleptics have been studied in many randomized controlled trials in different patient populations. The benefits of risperidone in the treatment of patients with aggression and agitation were noted. The benefits of quetiapine in the treatment of depression in patients with schizophrenia should be noted. Many years of experience using amisulpride indicate the benefits of low doses in controlling negative symptoms. One of the latest atypical antipsychotic drugs to appear on the pharmaceutical market is aripiprazole. Unlike other drugs in its range, it is not a D2 receptor antagonist but a partial agonist. This causes a number of its properties, including a low risk of extrapyramidal symptoms and hyperprolactinemia compared to other atypical neuroleptics. Examples of products with proven bioequivalence in the Ukrainian market are Farmlyga products: Arilentals (aripiprazole), Risperon (risperidone), Quetixol (quetiapine) and Soleks (amisulpride).